🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,136 results for “Lianyungang” Clear

  1. Sintilimab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  2. Sintilimab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma (NPC)

    phase 2 small molecule active

    1 trial

  3. Sintilimab

    The First People's Hospital of Lianyungang

    Multiple Primary Lung Cancer

    phase 2 small molecule active

    1 trial

  4. Sintilimab

    The First People's Hospital of Lianyungang

    Small Cell Lung Cancer Limited Stage

    phase 2 small molecule active

    1 trial

  5. Sintilimab

    The First People's Hospital of Lianyungang

    Carcinoma

    phase 2 mab active

    1 trial

  6. Sintilimab Combined with Platinum-containing Chemotherapy

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  7. Sintilimab with Interleukin-2+CAPOX

    The First People's Hospital of Lianyungang

    Locally Advanced Rectal Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  8. Sintilimab,nab-paclitaxel and tegio

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  9. Sodium stibogluconate

    The First People's Hospital of Lianyungang

    Myelodysplastic Syndromes

    phase 2 small molecule active

    1 trial

  10. Sonodynamic therapy(SDT)

    The First People's Hospital of Lianyungang

    Peripheral Arterial Disease

    phase 2 other terminated

    1 trial

  11. Stem Cell Educator

    The First People's Hospital of Lianyungang

    Alopecia Areata

    phase 2 other active

    1 trial

  12. Systemic chemotherapy (FOLFIRI)

    The First People's Hospital of Lianyungang

    Rectum Cancer

    phase 2 small molecule completed

    1 trial

  13. TACE and HAIC Combined With Regorafenib

    The First People's Hospital of Lianyungang

    Liver Metastasis Colon Cancer

    phase 2 other completed

    1 trial

  14. TACE with adebrelimab and bevacizumab

    The First People's Hospital of Lianyungang

    Adebrelimab

    phase 2 small molecule active

    1 trial

  15. Tas-102(Suyuan) combined with bevacizumab

    The First People's Hospital of Lianyungang

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  16. Telitacicept

    The First People's Hospital of Lianyungang

    Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  17. Temozolomide

    The First People's Hospital of Lianyungang

    Cytokine-Induced Killer Cells

    phase 2 small molecule active

    1 trial

  18. The treatment group using pembrolizumab combined with anlotinib and radiotherapy and chemotherapy

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  19. Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections

    The First People's Hospital of Lianyungang

    Hematological Malignancy

    phase 2 small molecule active

    1 trial

  20. Tislelizumab

    The First People's Hospital of Lianyungang

    Pancreatic Neoplasms

    phase 2 small molecule active

    1 trial

  21. Tislelizumab

    The First People's Hospital of Lianyungang

    Biliary Tract Tumor

    phase 2 small molecule active

    1 trial

  22. Tislelizumab

    The First People's Hospital of Lianyungang

    HER2-positive or Mutated Advanced Colorectal Cancer

    phase 2 small molecule active

    1 trial

  23. Tislelizumab

    The First People's Hospital of Lianyungang

    Bladder Urothelial Carcinoma

    phase 2 small molecule completed

    1 trial

  24. Tislelizumab combined with chemoradiotherapy

    The First People's Hospital of Lianyungang

    ESCC

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources